Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5)
Based on 1 publication(s) in Google Scholar
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonal antibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8+ cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer.
For research use only. We do not sell to patients.
- Purity : 99.47%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5)
More
Biological Activity
Description
Isotype
Armenian hamster IgG
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
CXCL9/MIG
In Vivo
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) (200 μg, i.p., once every 2 days, until complete cessation of graft beating) significantly prolongs the survival time of transplanted hearts and inhibits T cell activation in male C57BL/6J mice[2].
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) (250 μg, i.p., twice weekly, for 2 weeks) reduces the proportion of stem lines and increases the survival of side lines in male NPK mice with prostate cancer induced by Tamoxifen (HY-13757A)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5×105 E.G7-OVA cells or 1×106 B16-F10 cells injected C57BL/6 mice (7-10 weeks)[1]
-
Dosage:100 μg
-
Administration:Intraperitoneal injection (i.p.), once every 3 days for 2 dose
-
Result:Significantly reduced CTLs infiltration in tumors.
-
Animal Model:Male C57BL/6J mice (8-10 weeks)[2]
-
Dosage:200 μg
-
Administration:Intraperitoneal injection (i.p.), once every 2 days until complete cessation of graft beating
-
Result:Significantly prolonged median survival time.
Significantly reduced the level of acute cellular rejection in transplants.
Significantly reduced the proportion and absolute number of CD44+CXCR3+ effector T cells (CD4+ and CD8+).
-
Animal Model:Tamoxifen (10.8 mg/40 g, i.g., single dose, at two months of age) induced male NPK mice[3]
-
Dosage:250 μg
-
Administration:Intraperitoneal injection (i.p.), twice weekly for 2 weeks
-
Result:Reduced the proportion of stem lines.
Increased the survival of side lines.
Promoted the local invasiveness of stem lines.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo CXCL9 neutralization; Immunofluorescence
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
JCI Insight
ANGPTL8 links refeeding to monocyte dynamics and metabolic inflammation via the CCL5-CCR5 axis. [Abstract]2025 Nov 25:e196605. PMID: 41289013
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kamei M, et al. Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells. Int J Cancer. 2024 Jun 15;154(12):2176-2188. [Content Brief]
[2]. Chen Z, et al. Single-Cell RNA sequencing reveals immune cell dynamics and local intercellular communication in acute murine cardiac allograft rejection. Theranostics. 2022 Aug 29;12(14):6242-6257. [Content Brief]
[3]. Tshering LF, et al. Immune mechanisms shape the clonal landscape during early progression of prostate cancer. Dev Cell. 2023 Jun 19;58(12):1071-1086.e8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) Related Classifications
HY-P990255 Related Classifications
Powered by Bioz